A literature review was undertaken to develop a 'sustainability scorecard' of 10 elements that characterise a sustainable environment for biosimilars. Country policy landscape assessments were then conducted, and followed by two international advisory boards to inform the development of actionable policy recommendations.
CRA Literature Review
These elements were selected as an objective rating system to evaluate the level of sustainability of biosimilar policy environment in each market.
Click the icons below to learn more
Ensure safe and high-quality medicines
Facilitate cost savings for healthcare providers
Ensure healthy levels of supply
Maintain incentives for continued biologic research & innovation
Mitigate against biosimilar misconceptions
Facilitate efficient & streamlined patient access
Encourage multi-stakeholder decision-making
Facilitate sustainable levels of biosimilar competition
Increase prescribing options for patients & healthcare professionals
Maintain predictable market functioning
This paper seeks to address three key questions: